Oppenheimer & Co’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$5.08M Buy
40,398
+21,010
+108% +$2.64M 0.07% 315
2025
Q1
$2.14M Buy
19,388
+447
+2% +$49.4K 0.03% 523
2024
Q4
$2.59M Sell
18,941
-348
-2% -$47.5K 0.04% 480
2024
Q3
$2.22M Buy
19,289
+2,051
+12% +$236K 0.03% 516
2024
Q2
$2.37M Buy
17,238
+283
+2% +$39K 0.04% 473
2024
Q1
$2.34M Sell
16,955
-214
-1% -$29.5K 0.04% 468
2023
Q4
$2.26M Buy
17,169
+249
+1% +$32.8K 0.04% 462
2023
Q3
$1.9M Buy
16,920
+437
+3% +$49.2K 0.04% 479
2023
Q2
$1.55M Buy
16,483
+25
+0.2% +$2.36K 0.03% 544
2023
Q1
$1.67M Sell
16,458
-3,539
-18% -$358K 0.04% 502
2022
Q4
$2.39M Buy
19,997
+1,473
+8% +$176K 0.05% 393
2022
Q3
$1.97M Buy
18,524
+6,257
+51% +$664K 0.05% 433
2022
Q2
$1.2M Buy
12,267
+145
+1% +$14.1K 0.03% 623
2022
Q1
$1.14M Sell
12,122
-164
-1% -$15.4K 0.02% 698
2021
Q4
$1.05M Buy
12,286
+6,423
+110% +$547K 0.02% 761
2021
Q3
$562K Buy
5,863
+183
+3% +$17.5K 0.01% 969
2021
Q2
$553K Buy
5,680
+1,781
+46% +$173K 0.01% 983
2021
Q1
$379K Sell
3,899
-16
-0.4% -$1.56K 0.01% 1085
2020
Q4
$375K Buy
3,915
+128
+3% +$12.3K 0.01% 1001
2020
Q3
$364K Buy
3,787
+768
+25% +$73.8K 0.01% 915
2020
Q2
$369K Sell
3,019
-284
-9% -$34.7K 0.01% 899
2020
Q1
$286K Sell
3,303
-3,264
-50% -$283K 0.01% 914
2019
Q4
$706K Buy
6,567
+603
+10% +$64.8K 0.02% 727
2019
Q3
$537K Buy
5,964
+3,270
+121% +$294K 0.01% 770
2019
Q2
$227K Sell
2,694
-4,195
-61% -$353K 0.01% 1129
2019
Q1
$607K Buy
6,889
+1,773
+35% +$156K 0.02% 737
2018
Q4
$365K Sell
5,116
-1,329
-21% -$94.8K 0.01% 857
2018
Q3
$792K Buy
6,445
+3,068
+91% +$377K 0.02% 676
2018
Q2
$332K Sell
3,377
-159
-4% -$15.6K 0.01% 1018
2018
Q1
$293K Buy
+3,536
New +$293K 0.01% 1073
2014
Q1
Sell
-13,200
Closed -$124K 1448
2013
Q4
$124K Buy
+13,200
New +$124K ﹤0.01% 1295